CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
LY3164530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02221882
NCT02221882Phase 1Completed
CompareCT.gov

A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting Mesenchymal-Epithelial Transition Factor (MET) and Epidermal Growth Factor Receptor (EGFR), in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company·interventional·Posted Aug 21, 2014·Updated Oct 23, 2019

In Brief

A Phase 1 clinical trial evaluating LY3164530 for Neoplasms and Neoplasm Metastasis. Completed, enrolled 29 participants across 3 sites.

Detailed Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3164530 in participants with cancer that is advanced and/or has spread to another part(s) of the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Neoplasm Metastasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 21, 2014
Enrollment StartAug 1, 2014
Primary CompletionMar 7, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.9 years ago

Interventions

LY3164530drug

Administered IV.